dc.contributor.author | Tan, S H | |
dc.contributor.author | Yam, A W Y | |
dc.contributor.author | Lawton, L N | |
dc.contributor.author | Wong, R W J | |
dc.contributor.author | Young, R A | |
dc.contributor.author | Look, A T | |
dc.contributor.author | Sanda, T | |
dc.contributor.author | Young, Richard A. | |
dc.date.accessioned | 2017-02-10T16:09:48Z | |
dc.date.available | 2017-02-10T16:09:48Z | |
dc.date.issued | 2015-08 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.issn | 1476-5551 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/106891 | |
dc.description.abstract | T-cell acute lymphoblastic leukemia (T-ALL) is a malignant disorder resulting from the leukemic transformation of T-cell precursors, and is one of the most common forms of cancer in children and is also found in adults. The most frequent genetic abnormality in T-ALL is the dysregulation of transcription factor genes, including aberrant expression of TAL1/SCL. TAL1 is ectopically expressed in 40–60% of T-ALL cases owing to chromosomal translocation, intrachromosomal rearrangement (‘SIL-TAL deletion’) or a somatic mutation in a non-coding intergenic element. We previously reported that TAL1 forms a positive interconnected autoregulatory loop with its regulatory partners GATA3, RUNX1 and MYB (‘core regulatory circuits’). To identify critical downstream targets that contribute to T-cell leukemogenesis, we have also performed a loss-of-function RNA interference screen in the TAL1-positive T-ALL cell lines in our previous study.6 Among the high-confidence TAL1 targets, only four genes, including the Tribbles homolog 2 (TRIB2), were selected by this screen. TRIB2 is a pseudo-kinase protein and has been implicated as an oncogene that contributes to acute myeloid leukemia (AML) by negatively regulating the C/EBPα tumor suppressor protein. TRIB2 is also a transcriptional target of the oncogene NOTCH1 in T-ALL. However, the oncogenic role of TRIB2 in T-ALL pathogenesis, in particular, as a downstream consequence of the core regulatory circuits, has not been elucidated. In this study, we identified molecular pathways regulated by TRIB2 in T-ALL cells. | en_US |
dc.description.sponsorship | National Cancer Institute (U.S.) (Grants 1K99CA157951 and 5P01CA109901) | en_US |
dc.description.sponsorship | Singapore. National Research Foundation. Competitive Research Programme (Award NRF-NRFF2013-02) | en_US |
dc.language.iso | en_US | |
dc.publisher | Nature Publishing Group | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1038/leu.2015.195 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
dc.source | PMC | en_US |
dc.title | TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Tan, S H et al. “TRIB2 Reinforces the Oncogenic Transcriptional Program Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia.” Leukemia 30.4 (2016): 959–962. | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
dc.contributor.department | Whitehead Institute for Biomedical Research | en_US |
dc.contributor.mitauthor | Young, Richard A | |
dc.relation.journal | Leukemia | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Tan, S H; Yam, A W Y; Lawton, L N; Wong, R W J; Young, R A; Look, A T; Sanda, T | en_US |
dspace.embargo.terms | N | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-8855-8647 | |
mit.license | OPEN_ACCESS_POLICY | en_US |